MBX 4291
MBX Biosciences' investigational once-monthly GLP-1/GIP dual agonist prodrug for obesity — an extended-action approach that would substantially reduce dosing frequency versus weekly GLP-1/GIP agents like tirzepatide.
What is MBX 4291?
MBX 4291 is MBX Biosciences' investigational once-monthly GLP-1/GIP dual receptor agonist prodrug for chronic weight management. The molecule is designed as a sustained-release prodrug that produces continuous GLP-1/GIP receptor activation over a month following a single subcutaneous administration, addressing the dosing-frequency limitation of current weekly tirzepatide and semaglutide therapy. Phase 1 development is in progress as of mid-2026. The dosing interval positioning would compete with maritide (Amgen's once-monthly GLP-1/GIPR antagonist, separate mechanism) and with the broader GLP-1/GIP class on convenience.
What MBX 4291 Is Investigated For
MBX 4291 is an early-stage prodrug GLP-1/GIP dual agonist with engineered once-monthly pharmacokinetics. The mechanistic premise — extended-action prodrug chemistry producing continuous receptor activation — is biochemically reasonable and would compete with the weekly tirzepatide model on convenience. As of mid-2026, the program is Phase 1 stage with limited public data on efficacy or safety. The competitive landscape includes maritide (Amgen, once-monthly GLP-1 agonist plus GIPR antagonist, separate mechanism), VK2735 (Viking, weekly GLP-1/GIP), enicepatide/CT-388 (Roche, weekly GLP-1/GIP), and tirzepatide (approved weekly GLP-1/GIP).
History & Discovery
MBX 4291 emerged from MBX Biosciences' peptide engineering platform alongside the company's lead asset imapextide (GLP-1 antagonist for PBH) and amycretin prodrug MBX 5765. The once-monthly positioning differentiates MBX 4291 from weekly competitors (tirzepatide, VK2735, enicepatide) and aligns with maritide (Amgen's once-monthly GLP-1 agent, though with a different glucose-receptor mechanism). Gao and Borner (Appetite 2026, PMID 42492687) framed the GIPR-agonism (MBX 4291-class) versus GIPR-antagonism (maritide) contrast as the current class-mechanism divide in obesity pharmacotherapy — the definitive contemporary reference for how the two once-monthly approaches conceptually differ. Phase 1 development began in 2024–2025 with anticipated Phase 2 progression based on initial dose-escalation results.
How It Works
MBX 4291 is designed to be a one-shot-per-month version of tirzepatide-like obesity drugs. It releases GLP-1/GIP agonist activity slowly from a single injection over an entire month, instead of needing weekly injections. The mechanism on receptors is the same as tirzepatide; the difference is in how long one dose lasts.
MBX 4291 is engineered as a prodrug that releases active GLP-1/GIP dual agonist over an extended pharmacokinetic window — approximately one month. The specific chemistry (sustained-release depot formulation, slow-release prodrug, or alternative engineering approach) determines the release kinetics. Once the active agonist is released, receptor pharmacology mirrors tirzepatide and other GLP-1/GIP dual agonists — glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central anorectic effects. The engineering challenge for monthly dosing is producing sufficient peak receptor occupancy without exceeding tolerability thresholds during the early days post-injection, while maintaining therapeutic receptor occupancy through the end of the dosing interval. Phase 1 pharmacokinetic data will inform whether this profile can be achieved with the prodrug strategy.
Evidence Snapshot
Human Clinical Evidence
Phase 1 stage. Limited public data.
Animal / Preclinical
Adequate. GLP-1/GIP agonism is well-validated; prodrug chemistry is established.
Mechanistic Rationale
Strong. The dual GLP-1/GIP target is clinically validated through tirzepatide.
Research Gaps & Open Questions
What the current literature has not yet settled about MBX 4291:
- 01Phase 1 efficacy and safety data — pending publication.
- 02Dose-response and titration strategies in monthly dosing.
- 03Whether monthly profile produces equivalent efficacy to weekly tirzepatide.
- 04Long-term safety with monthly exposure.
- 05Adverse event management given the long pharmacological half-life.
Forms & Administration
Subcutaneous injection — once monthly anticipated. Investigational.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Phase 1 dose-escalation. Specific doses pending publication.
Frequency
Once monthly subcutaneous.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Chronic indefinite anticipated.
Protocol Notes
MBX 4291 is not commercially available. Phase 1 stage of development.
Investigational; not FDA-approved.
Timeline of Effects
Onset
To be characterized in Phase 1.
Peak Effect
Sustained over the monthly dosing interval per design.
After Discontinuation
Effects dissipate over weeks following the last dose given the long half-life — a notable consideration if adverse effects emerge.
Common Questions
Could once-monthly really replace weekly tirzepatide?
Potentially, for patients prioritizing convenience. The trade-offs are: (1) any adverse effects last longer with monthly dosing because the drug can't be quickly stopped, (2) dose-titration is more complex with longer intervals, and (3) plasma levels are flatter (no week-to-week pulses). Whether these are net improvements depends on patient preference and clinical results from Phase 2/3.
Who MBX 4291 Is NOT For
- •Pregnancy and breastfeeding.
- •Pediatric use — Phase 1 in adults.
- •Personal/family history of medullary thyroid carcinoma or MEN2 — class precaution.
- •History of severe pancreatitis — class precaution.
- •Severe gastroparesis — class consideration.
- •Known hypersensitivity.
Drug & Supplement Interactions
Class-level interactions for GLP-1/GIP agonists apply — slowed gastric emptying may affect concurrent oral drug absorption; hypoglycemia risk with insulin or sulfonylureas. The long pharmacokinetic profile of MBX 4291 means interaction considerations persist for weeks after a single dose.
Safety Profile
Common Side Effects
Cautions
- • Investigational — Phase 1
- • Class GLP-1/GIP precautions apply
What We Don't Know
Long-term safety, efficacy, and dose-response — under investigation.
Legal Status
United States
Investigational. Not FDA-approved.
International
Investigational.
Sports & Competition
Not currently named on WADA list; class considerations apply.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Once-monthly is always better than once-weekly.
Reality
Convenience improves with longer intervals, but tolerability and adverse-event management worsen because the drug cannot be quickly discontinued. The net benefit depends on individual patient priorities and tolerability profile from Phase 2/3 trials.
Published Research
3 studiesA Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy.
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
Gao and Borner, Appetite July 2026. Class-mechanism review directly comparing GIPR agonism (MBX 4291-class) versus GIPR antagonism (maritide) approaches to obesity pharmacotherapy — the definitive contemporary framing for the exact mechanism contrast the MBX 4291 file draws in its competitive positioning.
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Quick Facts
- Class
- Once-Monthly GLP-1 / GIP Dual Agonist Prodrug
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Sep 2026
- Citations
- 3PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.